Evotec AG has announced the acquisition of the Germany-based Bionamics GmbH. Bionamics is an asset management company that focuses on the translation of academic innovations into attractive assets for the biotech and Pharma industry.

The transaction comprises the acquisition of all shares of Bionamics against cash and future milestone payments. Next to an experienced management team Bionamics brings a portfolio of highly attractive and fully funded projects especially in neurodegeneration and CNS to Evotec.

Further financial details of the transaction remain undisclosed.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: "With the acquisition of Bionamics we accelerate our EVT Innovate strategy and enlarge our reach towards outstanding innovations. We welcome the openness of Bionamics to join the discovery infrastructure of Evotec. We are also very happy to welcome Dr Timm Jessen back at Evotec. In his new management role, Dr Jessen will be responsible for the commercialization of "EVT Innovate" projects."

Dr Timm Jessen, Managing Director of Bionamics GmbH, commented: "We highly value Evotec's strategic appreciation of our work and its success as demonstrated e.g. in managing the NEU² programme, a consortium of academic, biotech and Pharma partners focussing on novel products to treat Multiple Sclerosis and other neurodegenerative diseases. The combination of our management skills with Evotec's strong operational capabilities offers a unique constellation for researchers and entrepreneurs around the globe to accelerate their innovation together with us. I very much look forward to expand this concept further within the Evotec Group."